Product Description
Three transfusion-dependent beta-thalassaemia subjects aged 18-35 years will be reinfused with beta-globin restored autologous hematopoietic stem cells modified with LentiHBBT87Q. (Sourced from: https://clinicaltrials.gov/study/NCT05864170?term=LentiHBBT87Q&rank=2)
Mechanisms of Action: Stem Cell Therapy
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shenzhen Hemogen
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|